IL-17 RA & IL-17 RC

IL-17 RA & IL-17 RC Molekülinformation

Englischer Name	Interleukin-17 receptor A	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	2	Target-Alias	CDw217，IL-17 receptor A，IL17R，IL17RA，Interleukin 17 Receptor A，IL-17RA，Interleukin 17 Receptor，CD217 Antigen，HIL-17R，CANDF5，CD217，IMD51，Interleukin-17 receptor A
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Interleukin-17 receptor A
Target-Alias	CDw217，IL-17 receptor A，IL17R，IL17RA，Interleukin 17 Receptor A，IL-17RA，Interleukin 17 Receptor，CD217 Antigen，HIL-17R，CANDF5，CD217，IMD51，Interleukin-17 receptor A
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	2
Höchste Forschungs- und Entwicklungsphase	Approved

IL-17 RA & IL-17 RC Produktliste

Attribut
Protein (1)Cell (1)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
Fc Tag (1)- (1)
Marker
Unconjugated (1)- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CHEK-ATF133	Human	HEK293	Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell				In den Warenkorb legen
ILC-H5257	Human	HEK293	Human IL-17 RA&IL-17 RC Heterodimer Protein, Fc Tag&Fc Tag (MALS verified)				In den Warenkorb legen

Gesamtmenge2

Produktanfrage

IL-17 RA & IL-17 RC Molekülhintergrund

Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation.

IL-17 RA & IL-17 RC Molekülalias

IL-17 RA & IL-17 RC,IL-17RA & IL-17RC,CD217 & IL-17 RC

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
XCUR-17	XCUR-17	Phase 1 Clinical	Exicure Inc	Psoriasis	Details
PN-881	PN-881	Phase 1 Clinical	Protagonist Therapeutics Inc	Dermatitis; Psoriasis	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Brodalumab	AMG-827; KHK-4827; IL-17R mAb; MEDI-6365	Approved	Amgen Inc	Siliq, Lumicef, Kyntheum, 立美芙	Japan	Psoriasis; Arthritis, Psoriatic	Kyowa Kirin Co Ltd	2016-07-04	Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Axial Spondyloarthritis; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Crohn Disease; Esophageal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Hidradenitis Suppurativa; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Mouth Neoplasms; Non-radiographic axial spondyloarthritis; Palmoplantar pustulosis; Pancreatic Neoplasms; Plaque psoriasis; Prostatic Neoplasms; Psoriasis; Pustular psoriasis; Rectal Neoplasms; Scleroderma, Systemic; Skin Neoplasms; Solid tumours; Spondylitis, Ankylosing; Stomach Neoplasms; Testicular Neoplasms; Thyroid Neoplasms	Details